306
Views
13
CrossRef citations to date
0
Altmetric
Short Report

Preclinical Evaluation of a Chimeric Malaria Vaccine Candidate in Montanide ISA 720®: Immunogenecity and Safety in Rhesus Macaques

Pages 222-226 | Published online: 25 Sep 2006
 

Abstract

Several malarial antigens are in development as potential vaccine candidates as part of a concerted effort to control the disease, which kills more than one million people per year. Although some antigens have demonstrated an impact against the malaria parasite, Plasmodium falciparum, many researchers hypothesize that a combination of antigens will be required to generate high levels of efficacy against clinical disease. PfCP2.9 is a chimeric protein that includes MSP119 and domain III of AMA1 [AMA1 (III)] of Plasmodium falciparum in a single recombinant molecule. The antigen, formulated in Seppic’s ISA 720 adjuvant, is approaching Phase I clinical testing in humans.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.